Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes.
Acetyl glyceryl ether phosphorylcholine (AGEPC) and leukotriene B4 (LTB4) induce concentration-dependent neutrophil aggregation. On a molar basis, LTB4 is approximately 10 to 100 times more potent than AGEPC. AGEPC-induced aggregation is attenuated by two inhibitors of arachidonate lipoxygenation, eicosatetraynoic acid and nordihydroguaiaretic acid, and to a lesser extent by the cyclooxygenase inhibitor, indomethacin. LTB4-induced aggregation is not readily reduced by the above inhibitors of arachidonic acid metabolism. Reverse phase high performance liquid chromatography, coupled with selective ion gas chromatography/mass spectrometry, shows that AGEPC stimulates neutrophils to synthesize sufficient LTB4 to account for the AGEPC response. In addition, the rate of LTB4 biosynthesis in response to AGEPC correlates well with the rate of AGEPC- and/or LTB4-induced neutrophils aggregation, and desensitization experiments indicate that AGEPC and LTB4 cross-desensitize. These data suggest that AGEPC-induced neutrophil aggregation may be mediated by LTB4.
D015117:5,8,11,14-Eicosatetraynoic Acid / Q000494:pharmacology; D002396:Catechols / Q000494:pharmacology; D002449:Cell Aggregation; D002849:Chromatography, Gas; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007975:Leukotriene B4 / Q000032:analysis / Q000096:biosynthesis*; D009637:Masoprocol; D013058:Mass Spectrometry; D009504:Neutrophils / Q000378:metabolism* / Q000502:physiology; D010972:Platelet Activating Factor / Q000502:physiology*
D002396:Catechols; D010972:Platelet Activating Factor; D015117:5,8,11,14-Eicosatetraynoic Acid; D007975:Leukotriene B4; D009637:Masoprocol